The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance

Pharmacogenomics Journal

Volumn 10, Issue 6, 2010, Pages 489-504

  Reed, K ^a,b   Hembruff, S L ^b   Sprowl, J A ^a,b   Parissenti, A M ^a,b,c  

^a LAURENTIAN UNIVERSITY   (Canada)

^b SUDBURY REGIONAL HOSPITAL   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

ABCB1; breast cancer; drug resistance; epirubicin; paclitaxel; promoter hypomethylation

Indexed keywords

DOXORUBICIN; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 78649327794     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.1     Document Type: Article

References (49)

1. Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003 290 177-194.
2. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912-920.
3. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001; 33: 453-458.
4. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997; 3: 2025-2032.
5. 0 region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet 1997; 23: 391-400.
6. 0 CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 1999; 262: 924-932.
7. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET et al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007; 67: 955-967.
8. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther 2004; 3: 540-548.
9. Liscovitch M, Ravid D. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 2007; 245: 350-352.
10. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006; 231: 87-93.
11. Chen KG, Wang YC, Schaner ME, Francisco B, Duran GE, Juric D et al. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 2005; 65: 9388-9397.
12. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005; 24: 8061-8075.
13. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M et al. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 2008; 8: 318.
14. Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009; 19: 477-488.
15. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004; 85: 31-51.
16. Reed K, Hembruff SL, Laberge ML, Villeneuve DJ, Cote GB, Parissenti AM. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells. Epigenetics 2008; 3: 270-280.
17. Hembruff SL, Villeneuve DJ, Parissenti AM. The optimization of quantitative reverse transcription PCR for verification of cDNA micro-array data. Anal Biochem 2005; 345: 237-249.
18. Gomez-Martinez A, Garcia-Morales P, Carrato A, Castro-Galache MD, Soto JL, Carrasco-Garcia E et al. Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 2007; 5: 641-653.
19. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003; 278: 10344-10352.
20. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK et al. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 2006; 45: 365-374.
21. Kitada K, Yamasaki T. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites. Cancer Genet Cytogenet 2007; 178: 120-127.
22. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y et al. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007; 173: 1-9.
23. Chen GK, Lacayo NJ, Duran GE, Wang Y, Bangs CD, Rea S et al. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer 2002; 34: 372-383.
24. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
25. Tada Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000; 6: 4618-4627.
26. Reed K, Poulin ML, Yan L, Parissenti AM. Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation. Anal Biochem 2010; 397: 96-106.
27. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002; 22: 1844-1857.
28. 0-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28: 752-771.
29. Milani L, Lundmark A, Nordlund J, Kiialainen A, Flaegstad T, Jonmundsson G et al. Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res 2009; 19: 1-11.
30. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-1756.
31. Plass C. Cancer epigenomics. Hum Mol Genet 2002; 11: 2479-2488.
32. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987; 262: 17432-17436.
33. 0 sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 1993; 268: 8290-8297.
34. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990; 265: 221-226.
35. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22: 7496-7511.
36. Scotto KW, Egan DA. Transcriptional regulation of MDR genes. Cytotechnology 1998; 27: 257-269.
37. Hu Z, Jin S, Scotto KW. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000; 275: 2979-2985.
38. Cornwell MM, Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993; 268: 19505-19511.
39. Goldsmith ME, Madden MJ, Morrow CS, Cowan KH. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 1993; 268: 5856-5860.
40. Miyazaki M, Kohno K, Uchiumi T, Tanimura H, Matsuo K, Nasu M et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem Biophys Res Commun 1992; 187: 677-684.
41. Borellini F, Aquino A, Josephs SF, Glazer RI. Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells. Mol Cell Biol 1990; 10: 5541-5547.
42. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. Mutant p53 cooperates with ETS and selectively upregulates human MDR1 not MRP1. J Biol Chem 2001; 276: 39359-39367.
43. Ince TA, Scotto KW. Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. Cancer Res 1996; 56: 2021-2024.
44. Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005; 11(24 Part1): 8837-8844.
45. Ogura M, Takatori T, Sugimoto Y, Tsuruo T. Identification and characterization of three DNA-binding proteins on the promoter of the human MDR1 gene in drug-sensitive and -resistant cells. Jpn J Cancer Res 1991; 82: 1151-1159.
46. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001; 276: 27716-27720.
47. Ogretmen B, Safa AR. Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/ VCR human acute myeloid leukemia cell line. Biochemistry 2000; 39: 194-204.
48. Combates NJ, Rzepka RW, Chen YN, Cohen D. NF-IL6, a member of the C/EBP family of transcription factors, binds and transactivates the human MDR1 gene promoter. J Biol Chem 1994; 269: 29715-29719.
49. Ogretmen B, Safa AR. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 1999; 38: 2189-2199.